BPA and risk assessment

Lancet Diabetes Endocrinol. 2020 Apr;8(4):270-271. doi: 10.1016/S2213-8587(20)30069-3.

Authors

Antoine Dupuis¹, Sylvie Rabouan², Virginie Migeot², Nicolas Venisse²

Affiliations

¹ INSERM CIC 1402, HEDEX research group, CHU Poitiers, and School of Medicine and Pharmacy, Université de Poitiers, 86000 Poitiers, France. Electronic address: [email protected].
² INSERM CIC 1402, HEDEX research group, CHU Poitiers, and School of Medicine and Pharmacy, Université de Poitiers, 86000 Poitiers, France.

PMID: 32197111
DOI: 10.1016/S2213-8587(20)30069-3

No abstract available

Publication types

Letter
Comment

MeSH terms

Benzhydryl Compounds*
Risk Assessment

Substances

Benzhydryl Compounds